← All trials
NCT05777109
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2023
- Primary completion
- Apr 5, 2024
- Completion date
- Apr 5, 2024
- First posted
- Mar 21, 2023
- Last posted
- Aug 23, 2023
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Haikou People's HospitalOverall official - principal investigator
- Shandong first medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.